Form 4 for ARMP Armata Pharmaceuticals, Inc.
Accepted 2024-03-18 00:00:00 ET · period of report 2024-03-14 · accession 0001104659-24-035723 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-18 | 2024-03-14 | ARMP | Birx Deborah | CEO, Dir | A - Grant | $0.00 | +60.0K | 260.0K | +30% | $0 |
| D | 2024-03-18 | 2024-03-14 | ARMP | Birx Deborah | CEO, Dir | A - Grant | $0.00 | +240.0K | 240.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-14 | A | A | 60,000 | $0.00 | 260,000 | D | — | — | |
| 2 | Derivative | Stock Options (Right to Buy) | 2024-03-14 | A | A | 240,000 | $0.00 | 240,000 | D | $3.38 · — to 2034-03-14 | 240,000 Common Stock | (F1) Twenty-five percent (25%) of the Stock Options shall vest on March 14th of each of 2025, 2026, 2027, and 2028. |